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ABSTRACT  
Background: An updated psoriatic arthritis (PsA) core outcome set (COS) for randomized controlled trials 
(RCTs) was endorsed at the Outcome Measures in Rheumatology (OMERACT) meeting in 2016. 
Objectives: Synthesize the evidence on measurement properties of patient reported outcome measures 
(PROMs) for PsA and thereby contribute to development of a PsA core outcome measurement set (COMS) 
as described by the OMERACT Filter 2.0. 
Methods: A systematic literature search was performed in EMBASE, MEDLINE and PsycINFO on Jan 1
st
 
2017 to identify full-text articles with an aim of assessing the measurement properties of PROMs in PsA. 
Two independent reviewers rated the quality of studies using the COnsensus based standards for the 
Selection of health Measurement INstruments (COSMIN) checklist, and performed a qualitative evidence 
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synthesis. 
Results: Fifty-five studies were included in the systematic review. Forty-four instruments and a total of 89 
scales were analysed. PROMs measuring COS domains with at least fair quality evidence for good validity 
and reliability (and no evidence for poor properties) included the Stockerau Activity Score for PsA 
(German), Psoriasis Symptom Inventory, visual analogue scale for Patient Global, 36 Item Short Form 
Health Survey Physical Function subscale, Health Assessment Questionnaire Disability Index, Bath 
Ankylosing Spondylitis Functional Index, PsA Impact of Disease questionnaire, PsA Quality of Life 
questionnaire, VITACORA-19,  Functional Assessment of Chronic Illness Therapy Fatigue scale and Social 
Role Participation Questionnaire.  
Conclusions: At least one PROM with some evidence for aspects of validity and reliability was available for 
six of the eight mandatory domains of the PsA COS.   
Keywords: psoriatic arthritis, OMERACT, COSMIN, patient reported outcome measures, measurement 
properties, systematic review 
 
INTRODUCTION 
Psoriatic arthritis (PsA) is a chronic inflammatory disease associated with a range of symptoms, co-
morbidities and reduced health related quality of life.[1
-
3] Based on patients’ and physicians’ perspectives 
as well as recent research developments, the Group for Research and Assessment of Psoriasis and Psoriatic 
Arthritis (GRAPPA) together with the Outcome Measures in Rheumatology (OMERACT) international 
consensus effort developed an updated core outcome set (COS) for PsA[4], describing the outcomes 
(domains) that should be measured and reported in all randomized controlled trials. The updated PsA COS 
was endorsed in May 2016 by OMERACT and includes the following mandatory (‘inner core’) domains: 
Musculoskeletal (MSK) disease activity, Skin disease activity, Pain, Patient global, Physical function, Health 
Related Quality of Life (HRQoL), Fatigue and Systemic inflammation. Four other domains (Participation, 
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Economic cost, Structural damage and Emotional well-being) were considered important but not 
mandatory (middle COS circle), and four domains (Sleep, Independence, Stiffness and Treatment burden) 
were placed in the “research agenda” (outer COS circle).[5] 
The OMERACT Filter 2.0 provides guidelines for developing a core outcome measurement set 
(COMS) which comprises the appropriate instruments to assess each COS domain.[6]  Great heterogeneity 
exists in instruments used for measuring the core domains of PsA, and several have been “borrowed” from 
other diseases without confirming their measurement properties in PsA.[7] Instruments should have 
evidence of validity, reliability and responsiveness as described in detail by the COnsensus based standards 
for the Selection of health Measurement INstruments organisation (COSMIN).[8] In addition, an instrument 
needs to be feasible and yield interpretable results.[9] These qualities are summarized by the original 
OMERACT Filter as ‘Truth, Discrimination and Feasibility’.[10] As highlighted by the OMERACT Filter 2.0, 
the COS development was not influenced by considering how to measure the domains; neither the type of 
assessment nor the availability of specific instruments was taken into account. Development of the PsA 
COMS therefore implies that subsequently all available instruments per COS domain are identified, 
evaluated and judged for overall applicability. To support this GRAPPA-OMERACT initiative, the 
objective of this systematic literature review was to synthesise the evidence for good measurement 
properties of patient reported outcomes measures (PROMS) in PsA and align instruments and COS 
domains.  
METHODS 
A protocol was uploaded to PROSPERO prior to initiation of the systematic review (PROSPERO: 
CRD42016032546). The review adheres to the COSMIN guidelines[11
-
13] and the Preferred Reporting 
Items for Systematic reviews and Meta-Analyses (PRISMA-statement).[14] 
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Literature search  
A research librarian (EMB) and the first-author (PH) performed a systematic search in MEDLINE via 
PubMed from 1966, EMBASE via OVID from 1974, and PsycINFO via OVID from 1806, all to 1 January 2017. 
The search was designed to identify all types of outcome measurement instruments in PsA. The search was 
limited to humans and consisted of two overall terms:  (1) Target population: MeSH subheadings and free 
text words in title/abstract (ti/ab) were combined by the Boolean operator ‘OR’ to search for the target 
population (PsA) in the databases; (2) Measurement properties: Search filters have been developed to 
improve the search of studies on measurement properties in MEDLINE and EMBASE.[15] We used the 
highly sensitive filter validated for MEDLINE (sensitivity of 97.4%) and the filter for EMBASE optimized for 
this search. In PsycINFO only the target population was searched. The full search strategy is available in 
supplementary Table A.   
Eligibility criteria  
Per protocol, studies were considered eligible if published as full text articles in the English language with 
an aim of developing or assessing measurement properties of outcome measurements in PsA patients. 
However, for feasibility reasons and to ensure applicability of the COSMIN guidelines, it was subsequently 
decided to evaluate only patient reported instruments in this review, and allocate the assessment of the 
remaining instruments to parallel work streams.  The stepwise eligibility and inclusion process is depicted 
in Figure 1. Studies evaluating instruments used solely for screening or diagnostic purposes were not 
eligible. Only studies including ≥50% patients with PsA or reporting PsA subgroup results separately were 
included.  
Selection of articles 
PH eliminated duplicates and the remaining references were assessed for eligibility by two independent 
reviewers (PH, KH). Titles, abstracts and full-text articles (when appropriate) were reviewed and selection 
was performed by consensus with involvement of co-authors (RC, LK, EMB, A-MO) if needed. Additional 
studies identified by co-authors or reviews were considered for inclusion. Search results were handled by 
Reference Manager 12 (Thomson Reuters, USA). 
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Extraction of study characteristics and description of PROM characteristics  
PH and KH independently extracted data on the characteristics of the studies (number, age and gender of 
participants, study setting and language). Characteristics of the PROMs (e.g., items, scoring, feasibility and 
availability) were obtained by PH from the questionnaires, background literature, user manuals or 
European League Against Rheumatism (EULAR) Outcome Measures Library[16] or by contacting 
authors/copyright holders.  
Mapping the PROMs to corresponding COS domains 
The working group, including Patient Research Partners (PRPs) (NG, MdW) reviewed the PROMs to achieve 
consensus on how to present them by COS domains.  Separate scales within a multi-scale instrument as 
well as summed scale scores were perceived as unique instruments and mapped by their corresponding 
COS domains.  Measurements of HRQoL were categorized as either health status surveys or health 
value/preference/utility assessments.  The latter were reported within the COS domain ‘economic cost’. 
  
Extraction and evaluation of the methodological study quality per measurement property per 
instrument 
The COSMIN checklist enables a critical evaluation of the methodological quality of studies investigating 
measurement properties[11]. A four-point system is provided to score the methodological quality of a 
study per measurement property as ‘excellent’, ‘good’, ‘fair’ or ‘poor’.[13] Four independent reviewers 
worked in teams of two (PH/LK, PH/AMO, PH/YYL) to reach consensus on the COSMIN ratings.  A third 
reviewer (CT or RC) resolved disagreements. Information on score interpretation (mean (SD) of scores, 
floor and ceiling effects, minimally (clinically) important difference/improvement (M(C)ID/MCII), minimal 
detectable change (MDC) and Patient Acceptable Symptom State (PASS)) was extracted. 
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Evaluation of the result of the measurement properties  
The results of measurement properties per instrument were evaluated (concurrently with the rating of the 
study methodology) as positive (+), indeterminate (?) or negative (-) per study in accordance with the 
quality criteria described by the ‘COSMIN & Core Outcome Measures in Effectiveness Trials (COMET) 
collaboration’.[17]  
Level of evidence for the quality of the measurement properties of PROMs in PsA  
To determine the overall level of evidence for a measurement property of an instrument, data were 
synthesized by combining the quality of the measurement property results, the methodological study 
qualities and the consistency of the findings[18,19] (Table 1).  
 
Table 1  Level of evidence for the quality of a measurement property 
Strong (+++) 
 
Strong (- - -) 
Consistent findings of good measurement property in multiple studies of good methodological 
quality or in one study of excellent methodological quality.  
Consistent findings of poor measurement property in multiple studies of good methodological 
quality or in one study of excellent methodological quality.  
Moderate (++) 
 
Moderate (- -) 
Consistent findings of good measurement property in multiple studies of fair methodological 
quality or in one study of good methodological quality. 
Consistent findings of poor measurement property in multiple studies of fair methodological 
quality or in one study of good methodological quality. 
Limited (+) 
Limited (-) 
One study of fair methodological quality with findings of good measurement property. 
One study of fair methodological quality with findings of poor measurement property 
Conflicting 
(±) 
Conflicting findings on the measurement property quality results across studies. 
Unknown (?) Only studies of poor methodological quality were identified. 
 
Reporting the results of the evidence synthesis 
As described by OMERACT[9], the COSMIN & COMET collaboration[17] and the Food And Drug 
Administration (FDA)[20] guidelines, evidence on validity (especially content validity) and reliability 
should be prerequisites for an instrument to be considered for further evaluation/application. If an instrument 
does not measure what it intends to or produces unreliable estimates, it is irrelevant to test for e.g., 
responsiveness. Thus, in the result section of this systematic review, we have chosen to highlight the 
‘candidate’ instruments per COS domain that have at least limited evidence on reliability and validity and 
no evidence for any poor measurement properties.  
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The main evidence synthesis includes all studies of a PROM but conflicting evidence on measurement 
properties across language versions is described for ‘candidate’ PROMs. Available values for Cronbach-α, 
interclass correlation coefficients (ICC) and floor/ceiling effects are described in the text while remaining 
results on measurement properties and score interpretation can be obtained from the tables. 
RESULTS 
Study selection 
As illustrated in Figure 1; from 5844 unique references identified, 334 studies were eligible for further 
assessment.  Of these, 77 reviews were excluded, as were 87 abstracts/conference papers without full-text. 
An additional 11 papers were added from experts and reference lists resulting in 181 studies for full-text 
reading. Eighty of these failed the inclusion criteria due to reasons depicted in Figure 1. Of the remaining 
101 studies, clinician-reported (n=18) and composite (n=28) measures were excluded due to the focus on 
PROMs only, leaving 55 studies for final inclusion.  
Study characteristics 
The included studies were published between 1992 and 2016 and were mainly observational cohorts of PsA 
patients in their 4
th
 and 5
th
 decades of life. Most studies were performed in English speaking countries and 
evaluated more than one PROM (Table 2).  
Characteristics of the PROMs 
A total of 44 instruments covering 89 separate PROMs were evaluated (supplementary Tables B1, B2).  
Each PROM was mapped to the corresponding COS domain. The content, scoring and feasibility aspects of 
each PROM are described in supplementary Table B2. 
Rating of the methodological quality and measurement property results of each study 
The methodological quality ratings and ratings of the measurement property results are presented for each 
PROM in supplementary Table C. A further description of the rating rationale and values for score 
interpretation are listed per PROM in supplementary Table D.  
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 Table 2 Characteristics of the studies 
N Sources 
(55 in 
total) 
PROM(s)  N
a 
Ps
A(
%) 
Age,m
ean(S
D) 
Wo
men(
%) 
Lang
uage 
Count
ry 
Set
tin
g 
1 Duffy 
(1992)[21] 
AIMS1 14
5 
10
0 
48(13) 43 Engli
sh 
Cana
da 
OP
C 
2 Blackmore 
(1995)[22] 
HAQ-DI, HAQ-S, VAS stiffness(HAQ), VAS pain(HAQ) 11
4 
10
0 
49(13) 39 Engli
sh 
Cana
da 
OP
C 
3 Husted 
(1995)[23] 
HAQ-SK 11
8 
10
0 
49(13) 39 Engli
sh 
Cana
da 
OP
C 
4 Husted 
(1996)[24] 
AIMS2  12
4 
10
0 
48(13) 40 Engli
sh 
Cana
da 
OP
C 
5 Husted 
(1996)[25] 
AIMS1, AIMS2  65 10
0 
46(12) 42 Engli
sh 
Cana
da 
OP
C 
6 Husted 
(1997)[26] 
SF-36  11
3 
10
0 
51(13) 38 Engli
sh 
Cana
da 
OP
C 
7 Taccari 
(1998)[27] 
HAQ-DI, AIMS1  72 10
0 
55(13) 31 Italia
n
b 
Italy
b 
OP
C 
8 Husted 
(1998)[28] 
AIMS2, HAQ-DI, VAS pain(HAQ), SF-36  70 10
0 
46(11) 39 Engli
sh 
Cana
da 
OP
C 
9 Navsarikar 
(1999)[29] 
DASH 50 10
0 
49(12) 44 Engli
sh 
Cana
da 
OP
C 
1
0 
McKenna 
(2004)[30] 
PsAQoL 28
6 
10
0 
50(13) 68 Engli
sh 
UK OP
C 
1
1 
Taylor 
(2004)[31] 
BASDAI 13
3 
10
0 
46(19)
/52(25
)
c
 
41/5
3
c
 
Engli
sh 
New 
Zeala
nd 
OP
C 
1
2 
Chandran 
(2007)[32] 
FACIT-Fatigue 13
5 
10
0 
52(13) 41 Engli
sh 
Cana
da 
OP
C 
1
3 
Taylor 
(2007)[33] 
HAQ-DI, SF-36 PF 27
6 
49 52(14)
d
 
43
d
 Engli
sh 
New 
Zeala
nd  
OP
C 
1
4 
Leung 
(2008)[34] 
HAQ-DI, BASFI, DFI, SF-36 PF 10
8 
10
0 
49(13) 52 Chin
ese 
China OP
C 
1
5 
Healy 
(2008)[35] 
PsAQoL 28 10
0 
47(11) 50 Engli
sh 
UK OP
C 
1
6 
Domingue
z(2009)[3
6] 
PASE 19
0 
19 NS NS Engli
sh 
USA OP
C 
1
7 
F.-Sueiro 
(2010)[37] 
BASDAI 20
3 
49 55(13)
d
 
36
d
 Span
ish 
Spain OP
C 
1
8 
Minnock 
(2010)[38] 
NRS Fatigue 41 10
0 
45(13) 54 Engli
sh 
Irelan
d
b
 
OP
C 
1 Eder BASDAI 20 10 53(14) 37 Engli Cana OP
10 
 
9 (2010)[39] 1 0 sh da C 
2
0 
Leung 
(2010)[40] 
SF-36, MCS, PCS 16
8 
10
0 
48(12) 46 Chin
ese 
China OP
C 
2
1 
Billing 
(2010)[41] 
PsAQoL 12
3 
10
0 
51(15) 53 Swe
dish 
Swed
en 
OP
C 
2
2 
Brodszky 
(2010)[42] 
PsAQoL, HAQ-DI, EQ-5D-3L 18
3 
10
0 
50(13) 57 Hun
garia
n 
Hung
ary 
OP
C 
2
3 
Kwok 
(2010)[43] 
VAS-pain/sleep/global/ fatigue, HAQ-DI 20
0 
10
0 
51(14) 59 Engli
sh 
Cana
da 
OP
C 
2
4 
El 
Miedany 
(2010)[44] 
MultiP scales (NRS pain, NRS global (joints), NRS 
fatigue, mRAI, PR-TJC, NRS stiffness, CIAQ-QoL, 
CIAQ-FI) 
46
2 
26.
6 
60(10) 72 Engli
sh
 
UK, 
Egypt 
OP
C 
2
5 
Kvamme 
(2010)[45] 
EQ-5D-3L, VAS-global/pain, mHAQ, SF-6D 42
25 
20.
1 
48(12)
d
 
47
c
 Nor
wegi
an 
Norw
ay 
OP
C 
2
6 
Hu 
(2010)[46] 
WTP  59 10
0 
Range: 
23-89 
44 Engli
sh 
USA OP
C 
2
7 
Adams 
(2010)[47] 
EQ-5D-3L, SF-6D 50
4 
32 45(13) 52 Engli
sh 
Irelan
d 
OP
C 
2
8 
Adams 
(2011)[48] 
EQ-5D-3L 50
4 
32 45(13) 52 Engli
sh 
Irelan
d 
OP
C 
2
9 
Cauli 
(2011)[49] 
VAS-global/skin/joints 31
9 
10
0 
52(13) 42 Mult
iple 
Sever
al 
OP
C 
3
0 
Leung  
(2011)[50] 
SF-36, VAS pain, VAS global, HAQ-DI 20 10
0 
48(13)
/52(11
)
e 
46/3
7
e 
Chin
ese 
China OP
C 
3
1 
Mease 
(2011)[51] 
HAQ-DI 16
1 
10
0 
47(11) 52 Engli
sh  
USA  RC
T 
3
2 
Davis 
(2011)[52] 
SRPQ 10
9 
60 53(11) 37 Engli
sh 
Cana
da 
OP
C 
3
3 
Leung 
(2012)[53] 
NRS-global 12
5 
10
0 
48(12) 48 Chin
ese 
China OP
C 
3
4 
Leung  
(2013)[54] 
EQ-5D-3L, SF-6D 86 10
0 
49(13) 52 Eng/
Chin 
Singa
pore 
OP
C 
3
5 
Wink 
(2013)[55] 
PsAQoL 18
3 
10
0 
55(13) 45 Dutc
h 
Nethe
rlands 
OP
C 
3
6 
Coaccioli 
(2014)[56] 
PAIP 12
3 
66 50 
(22-
82) 
53 Italia
n 
Italy OP
C 
3
7 
Osterhaus 
(2014)[57] 
WPS 40
9 
10
0 
48(11) 55 Mult
iple 
Sever
al 
RC
T 
3
8 
Gossec 
(2014)[58] 
PsAID-9, PsAID-12 47
4 
10
0 
50(13) 50 Mult
iple 
Sever
al 
OP
C 
3
9 
Torre-
Al.(2014)[
59] 
VITACORA-19  32
3 
65 50(19)
d
 
43
d
 Span
ish 
Spain OP
C 
4 Katchama HAQ-DI 47 10 49(10) 55 Thai Thaila OP
11 
 
0 rt(2014)[6
0] 
0 nd C 
4
1 
Lebwohl(2
014)[61] 
PSD 29
/1
6
g 
34
/5
0
g
 
39(22-
59)
f
 
31
f
 Engli
sh 
USA OP
C 
4
2 
Chiricozzi 
(2015)[62] 
PsoDisk  31 61.
3 
52(14)
f
 42
f
 Italia
n 
Italy OP
C 
4
3 
Lubrano 
(2015)[63] 
VAS-global 12
4 
10
0 
52(42-
61) 
53 Italia
n 
Italy OP
C 
4
4 
Talli 
(2015)[64] 
NRS-global/joints/skin 22
3 
10
0 
51(13) 51 Mult
iple 
Sever
al 
OP
C 
4
5 
Leeb 
(2015)[65] 
SASPA 15
2 
10
0 
54(26-
80) 
46 Ger
man 
Austri
a 
OP
C 
4
6 
Naegeli 
(2015)[66
] 
Worst Itch NRS 34 65 54(14) 50 Engl
ish 
USA OP
C 
4
7 
Wilson 
(2015)[67] 
PSI 15
4 
10
0 
52(11) 63 Engli
sh 
USA/
Cana
da 
RC
T 
4
8 
de Wit 
(2015)[68] 
PsAID 47
4 
10
0 
50(13) 50 Mult
iple 
Sever
al 
OP
C 
4
9 
Tander 
(2016)[69] 
VITACORA-19 61 10
0 
47(12) 64 Turki
sh 
Turke
y 
OP
C 
5
0 
Piaserico 
(2016)[70] 
PASE 29
8 
19
-
28 
NS 44
f
 Italia
n 
Italy OP
C 
5
1 
Leung 
(2016)[71] 
PsAQoL 98 10
0 
52(14) 49 Eng/
Chin 
Singa
pore 
OP
C 
5
2 
Salaffi 
(2016)[72] 
PsAIDtouch 15
9 
10
0 
55(12) 61 Italia
n 
Italy OP
C 
5
3 
di Carlo 
(2016)[73] 
PsAID 14
4 
10
0 
51(13) 44 Italia
n 
Italy OP
C 
5
4
 
5
5 
Cohen 
(2016)[74] 
Cooper 
(2016)[75] 
IPBOD 
EQ-5D-3L  
16 
25
5 
50 
15 
56(17) 
49(14) 
69 
62 
Engli
sh 
Swe
den 
USA 
Swedi
sh  
OP
C 
OP
C 
 
a, Number of patients (n) often differs across the analyses within a study N in this table refers to the highest number 
of participants included; b,Presumed, not clearly stated; c, Axial PsA/Peripheral PsA; d, For the PsA group; e, Patient 
treated with TNFI <12 weeks/patients treated >12 weeks; f, Reported for all patients (not only PsA); g, Patients in the 
“concept elicitation”/“cognitive interview” investigation. Abbreviations: AIMS, Arthritis Impact Measurement Scale; 
BASDAI, Bath Ankylosing Spondylitis Activity Index; BASFI, Bath Ankylosing Spondylitis Functional index; Chin, 
Chinese; CIAQ-FI, Combined Inflammatory Arthritis – Functional Impairment questionnaire; CIAQ-QoL, Combined 
Inflammatory Arthritis – quality of life questionnaire; DASH, Disabilities of the Arm, Shoulder and Hand Outcome 
Measure; DFI; Dougados Functional Index; EQ-5D-3L, EuroQoL 5 Dimensions questionnaire with 3 response levels; 
Eng, English; FACIT-Fatigue, Functional Assessment of Chronic Illness Therapy-Fatigue Scale;  Fi, Functional 
Index; HAQ, Health Assessment Questionnaire (HAQ-S: Spondyloarthropathy, HAQ-SK: Skin, HAQ-DI: Disability 
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Index); IPBOD, Inverse Psoriasis Burden of Disease questionnaire; mRAI, Modified Rheumatology Attitude Index; 
MultiP, Multidimensional Patient Reported Outcome Questionnaire; NRS, Numeric Rating Scale; NS, Not stated; 
OPC, Outpatient Clinic; PAIP, Psoriatic Arthritis Impact Profile; PASE, PsA Screening and Evaluation Questionnaire; 
PsoDisk, abbreviation not further explained; PR-TJC, Patient-reported-tender-joint-count; PsA, Psoriatic Arthritis; 
PsAID, Psoriatic Arthritis Impact of Disease questionnaire; PsAQoL, PsA Quality of Life instrument; RCT, 
Randomised controlled trial; SASPA, Stockerau Activity Score for Psoriatic Arthritis; SF-6D, utility tool derived from 
SF-36 comprising six multi-level dimensions; SF-36, Medical Outcome Survey Short Form 36-item Health Survey 
(SF-36 MCS: Mental Component Summary, PCS: Physical Component Summary, PF: SF-36 physical function 
subscale; PSI, Psoriasis Symptom Inventory; SRPQ, Social Role Participation Questionnaire; VAS, Visual Analogue 
Scale;  VITACORA-19, Spanish acronym, full name not available; WTP, Willingness to Pay Questionnaire; WPS, 
Work Productivity Survey. 
 
Level of evidence on the measurement properties for each of the evaluated PROMs  
Table 3 presents the overall evidence synthesis. Generally, most studies were of poor or fair quality 
resulting in limited or unknown evidence for the evaluated measurement properties. According to the results 
of the COSMIN analyses (supplementary Table D), frequent methodological limitations were small sample 
sizes, lack of information on handling of missing data, lack of information on unidimensionality when 
assessing internal consistency, insufficient methods for examining/reporting content validity, inappropriate 
statistical methods for testing responsiveness, and lack of hypotheses and psychometric information on 
comparators when testing construct validity. 
Evidence for PROMS measuring PsA core domains  
MUSCULOSKELETAL DISEASE ACTIVITY.  
The core domain of musculoskeletal disease activity is currently measured using a combination of physician 
assessments (clinical examination) and PROMs, and depending on the purpose of the study also biologic 
inflammatory markers and/or assessments of PsA pathophysiology using tissue imaging techniques. Six 
PROMs that aim to evaluate the concept of patient reported disease activity were retrieved (Table 3). The 
Stockerau Activity Score for Psoriatic Arthritis (SASPA) in German was currently the best candidate based 
on limited evidence for unidimensionality, internal consistency (Cronbach-α=0.875) as well as structural 
validity by factor analysis (supplementary Table C and D). SASPA is short, free and easy to score 
(supplementary Table B2). The main limitations of SASPA are the unknown content validity and only the 
13 
 
original German version was evaluated. SASPA is available in English but without information on the 
quality of the translation or cross-cultural validation.  
SKIN DISEASE ACTIVITY 
Three instruments were found that aim to measure patient reported skin disease activity (Table 3). Strong 
evidence for content validity of the Psoriasis Symptom Diary (PSD) was obtained while information on 
remaining measurement properties was not available in PsA. Based on results from Rasch and principal 
component analysis, the Psoriasis Symptom Inventory (PSI) appeared the best available PROM having 
moderate evidence for unidimensionality, internal consistency (Cronbach α=0.95) and structural validity, 
and limited evidence for responsiveness, test-retest reliability (ICC=0.70) and construct validity (external 
relationships and known group validity). The main limitations of PSI include item floor effects (up to 37% at 
baseline) (supplementary Table D).  
PAIN 
Six PROMs were evaluated (Table 3). None of these had evidence on both reliability and validity. The 
Medical Outcome Survey Short Form 36-item Health Survey Bodily Pain subscale (SF-36 BP) was 
evaluated by Chinese and English studies generating moderate and limited evidence for construct validity 
regarding internal and external relationships, respectively. Evidence for unidimensionality of the BP scale 
was not provided by the studies reporting on Cronbach-α (0.80-0.91) leading to no overall evidence for 
internal consistency.  Information on floor effects (1.2%), ceiling effects (3.0%) and MID was provided 
(supplementary Table D).  The main limitations of SF-36 BP are the unknown evidence for reliability and 
content validity, and the requirement of software to calculate scores (supplementary Table B2). The visual 
analogue scale (VAS) of pain (1 week recall time) had limited evidence for construct validity (external 
relationships) (Table 3), and MID was reported (Table 3, and  supplementary Table C and D). 
PATIENT GLOBAL 
Eight measures of Patient Global (PtG) were identified and included VAS and numeric rating scales (NRS) 
with varying recall periods. The phrasing of the PtG item addressed the impact on overall well-being of 
either 1) arthritis, 2) psoriasis, or 3) PsA (as a whole) as described in supplementary Table B2.  Only the 
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VAS of PtG due to PsA (1 week recall) had evidence of both validity and reliability in PsA including limited 
evidence for construct validity (external relationships) and moderate evidence for test-retest reliability (ICC 
(95%CI) =0.87(0.83-0.90)). Values of MID, PASS and MCII were reported across languages and recall 
versions of VAS PtG (Table 3, supplementary Tables C-E). The NRS of PtG due to PsA (1 week recall) had 
moderate evidence for construct validity (external relationships and known group validity) and floor/ceiling 
effects were reported up to ~ 8 %/3 % (Table 3 and supplementary Table D).  
PHYSICAL FUNCTION 
Twenty-three PROMs were evaluated (Table 3), and three of these had evidence on both reliability and 
validity including the Bath Ankylosing Functional Index (BASFI), the SF-36 Physical Function subscale 
(SF-36 PF) and the Health Assessment Questionnaire Disability Index (HAQ-DI). Based on evidence from 
English and Chinese studies using Rasch analysis and principal component analysis, the SF-36 PF was the 
best candidate with strong evidence for unidimensionality, internal consistency (Cronbach α=0.91-0.92) and 
good structural validity. Evidence for construct validity was moderate and limited for internal and external 
relationships, respectively (Table 3).  Floor and ceiling effects were less than 10% and MID was reported 
(supplementary Table D). The HAQ-DI was the most frequently assessed instrument for this domain and 
had strong evidence for good internal consistency and structural validity (Table 3). However Rasch analysis 
suggested better properties for the SF-36 PF in a study that compared the two instruments.[33] HAQ-DI was 
limited by floor effect (up to 50%) and had conflicting evidence on construct validity across languages 
(supplementary Tables C-E).  
HEALTH RELATED QUALITY OF LIFE/LIFE IMPACT 
Ten PROMs were identified (Table 3). Of these, the Psoriatic Arthritis Impact of Disease (PsAID) 
questionnaire, the PsA Quality of Life instrument (PsAQoL) and the VITACORA-19 (Spanish and Italian 
versions) all had some evidence on both reliability and validity. PsAID was translated and evaluated in 
several languages during the development phase and appeared a good candidate based on strong evidence 
for content validity and moderate evidence for good test-retest reliability and for good construct validity 
(external relationships) of the 12-item version (PsAID-12). Similar findings existed for PsAID-9 except that 
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evidence for construct validity was limited. Floor/ceiling effects of PsAID were <1%, and values for PASS 
were provided (supplementary Table D). The PsAQoL was assessed in several language versions 
(supplementary Tables C-E) generating strong evidence for unidimensionality and internal consistency 
(Cronbach α=0.91) and moderate evidence for test-retest reliability and structural, construct validity 
(external relationships and known group validity) (Tables 3). Moderate and strong evidence for content 
validity was available for the English and Swedish versions of PsAQoL, while limited evidence for poor 
content validity was achieved by a Dutch study where approximately half of the patients suggested a lack of 
items, resulting in overall conflicting evidence for this property (supplementary Tables C-E). Floor effect of 
PsAQoL was up to 19% (supplementary Table D). VITACORA-19 was evaluated in Spanish (origin) and in 
Turkish resulting in moderate evidence for test-retest reliability (ICC=0.94), content validity and construct 
validity (external relationships) as well as limited evidence for unidimensionality, internal consistency 
(Cronbach α= 0.95) and good structural validity. Floor/ceiling effects were <1% and MCID was defined 
(supplementary Table D). No formal English translation or cross-cultural validation was available.  
FATIGUE 
Four instruments were identified (Table 3). Evidence for validity and reliability was only available for the 
Functional Assessment of Chronic Illness Therapy-Fatigue scale (FACIT-Fatigue) including limited 
evidence for good test-retest reliability (ICC=0.95) and construct validity (external relationships) (Table 3, 
supplementary Table D).  
PROMs measuring domains of the middle circle of the PsA COS  
PARTICIPATION 
Eleven PROMs were evaluated (Table 3). The three subscales of the Social Role Participation Questionnaire 
were the only measurements with evidence of both reliability and validity including limited evidence for 
good test-retest reliability, content validity and construct (external relationships and known group) validity. 
The Work Productivity Survey had limited evidence for good construct validity and responsiveness but high 
floor effects found for certain items (73.7% (item 2) and 77.3% (item 8)) (Table 3, supplementary Table D). 
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The SF-36 role emotional, role physical and social functioning subscales had moderate evidence for good 
construct validity (hypotheses testing regarding known groups, internal and external relationships).  
EMOTIONAL WELL-BEING 
Nine instruments were identified from Chinese and English studies but none had evidence on both validity 
and reliability (Table 3).  The most information was available for the SF-36 Mental Health subscale (SF-36 
MH) and the SF-36 mental component summary (MCS) including moderate evidence for good construct 
(internal relationships) and structural validity, respectively (Table 3, supplementary Table D).  
ECONOMIC COST 
Four instruments were available (Table 3) but none of these had evidence for both reliability and validity. 
Evidence for construct validity (external relationships) was available for the EuroQol-5 Domain 3 level (EQ 
5D-3L) (moderate) and the SF-6D (derived from SF-36) and Willingness-to-pay questionnaire (both 
limited). Differences in utility estimates from EQ-5D versus SF-6D, score distribution, floor/ceiling effects, 
PASS and MCII information were reported (supplementary Table D).  
PROMs measuring domains of the COS research agenda (outer circle) 
SLEEP 
One study assessed VAS Sleep providing information on score interpretation (Table 3, supplementary Table 
D). 
STIFFNESS 
Two measurements, VAS Stiffness and the NRS Stiffness were evaluated (Table 3) but the evidence for 
measurement properties remained unknown (Table 3, supplementary Table D). 
PROMS measuring domains not included in the COS  
SF-36 general health subscale (GH) and the Arthritis Impact Measurement (AIMS 2) Social Support scale 
were evaluated but evidence for measurement properties was not achieved (Tables 3, supplementary Table 
D). 
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Table 3  Level of evidence for measurement properties per PROM  listed by matching COS domain  
PROMs by 
COS 
Domains 
(n=89) 
Reliability 
 COSMIN BOX (A-C) 
Validity 
 COSMIN BOX (D-H) 
Responsiven
ess COSMIN 
BOX (I) 
Info on 
score 
interpret
ation  
(values 
are 
provided 
in suppl. 
Table D)  
Internal 
consisten
cy 
Re-
lia 
bilit
y 
Mea
su-
re-
men
t 
erro
r 
Con-
tent 
validit
y 
Stru
ctu-
ral 
valid
ity 
Hypo
the-
ses 
testin
g 
Cross-
cult. 
Validit
y 
Crite-
rion 
validit
y 
Sensitivity to 
change 
 A B C D E F G H I  
MSK DISEASE ACTIVITY, patient 
reported aspects (n=6) 
       
BASDAI[31,37,
39]   
?     ±   ? F/C 
SASPA[65]  +    + ?   ?  
PASE-
total[36,70]  
 ?    + A  +  
PASE-
symptom[36,70]  
 ?    + A  +  
PASE-
function[36,70]  
 ?    + A  +  
PR-TJC[44]   ?  ?     
SKIN DISEASE ACTIVITY, patient 
reported aspects (n=3) 
       
PSI[67] ++ +   ++ +   + F/C 
PSD[61]    +++       
Worst itch 
NRS[66] 
   +       
PAIN (n=6)           
VAS Pain (1 week 
recall)[22,28,43,50] 
    +   ? MID 
VAS Pain (recall NS)[45]         MCII, 
PASS 
NRS Pain (1 
week recall)[44]  
 ?  ?  ?     
SF-36 
BP[26,28,40,50] 
?     +/++ 
b 
  ? MID, F/C 
AIMS1 
Pain[21,25,27] 
     ++   ?  
AIMS2 
Pain[24,25,28] 
?     +   ?  
PATIENT GLOBAL (n=8)          
Patient global due to 
psoriasis 
         
NRS (1 week recall)[64]     +    F/C  
VAS (1 week recall)[49] ++    ?     
Patient global due to 
arthritis 
         
NRS (1 week recall)[64]     +    F/C 
NRS (1 day recall)[44]   ?  ?     
VAS (1 week recall)[49] ++    ?     
Patient global due to PsA          
NRS (1 week recall)[53,64]     ++    F/C 
VAS (1 week 
recall)[43,49,50,63]  
++    +   ? MID 
VAS (recall NS)[45]           MID, 
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PASS, 
MCII 
Table 3 cont. 
 
PROMs by COS 
Domains 
Reliability 
 COSMIN BOX (A-C) 
Validity 
 COSMIN BOX (D-H) 
Responsiv
eness 
COSMIN 
BOX (I) 
Info on 
score 
interpreta-
tion  
(values are 
provided 
in suppl. 
Table D) 
Interna
l 
consiste
ncy 
Reliabi
lity 
Me
a-
su-
re-
me
nt 
err
or 
Con-
tent 
valid
ity 
Stru
ctu-
ral 
vali
dity 
Hyp
o-
the-
ses 
testi
ng 
Cross
-cult. 
Valid
ity 
Crite
rion 
valid
ity 
Sensitivity 
to change 
 A B C D E F G H I  
PHYSICAL FUNCTION 
(n=23) 
        Interpreta
bility 
DFI[34]  – –    – – ?    F/C 
DASH[29]       – –     
BASFI[34]  ++    ++ ?    F/C  
HAQ-DI 
[22,27,28,33,34,42,43,
50,51,60] 
+++    +++ ±   ? F/C, MID 
HAQ-S[22]        –     
HAQ-SK[23]      ?     
mHAQ[45]           PASS, 
MCII 
SF-36 
PF[26,28,33,34,40,50] 
+++    +++ +/++
b 
  ? F/C, MID 
SF-36 PCS[40,50]     ++ ?   ?  
MultiP CASQ-FI[44] ?    ? ?     
AIMS1 Mobility[21]      -     
AIMS1 Physical[21,27]      ±     
AIMS1 Dexterity[21]      +     
AIMS1 House[21]     +     
AIMS1 ADL[21]      –     
AIMS1 PC[25]         ?  
AIMS2 PC[25,28]          ?  
AIMS2 Mobility[24]      +     
AIMS2 Physical[24]      +     
AIMS2 Dexterity[24]     +     
AIMS2 Selfcare[24]      –     
AIMS2 House[24]      –     
AIMS2 Arm F.[24]     +     
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Table 3 cont.  
PROMs by COS 
Domains  
Reliability 
 COSMIN BOX (A-C) 
Validity 
 COSMIN BOX (D-H) 
Responsive
ness 
COSMIN 
BOX (I) 
Info on 
score 
interpre
tation  
(values 
are 
provi-
ded in 
suppl. 
Table 
D) 
Internal 
consiste
ncy 
Reliabil
ity 
Mea
su-
re-
men
t 
erro
r 
Con-
tent 
validi
ty 
Stru
ctu-
ral 
vali
dity 
Hyp
o-
the-
ses 
testi
ng 
Cross
-cult. 
Valid
ity 
Crite
rion 
validi
ty 
Sensitivity 
to change 
 A B C D E F G H I  
HRQoL/LIFE IMPACT (n=10) 
 
       
PsAQoL[30,35,41,4
2,55,71]  
+++ ++ ? ± ++ ++ a  ? F/C 
AIMS1 Global[27]       ?     
PsAID-9[58,68]  c ++  +++  + a  ? PASS, 
F/C  
PsAID-12[58,68,73]  c ++  +++ c ++ a  ? PASS, 
F/C    
touchPsAID-12[72]       +  +d          
MDA 
cut-off 
PAIP[56]       ?     
VITACORA-
19[59,69]  
+ ++  ++ + ++ a  ?  MCID, 
F/C 
PsoDisk[62]          ?  
MultiP CIAQ-QoL[44]  ?  ?  ?     
IBOD[74]  c   ?  ?     
FATIGUE (n=4)           
FACIT-Fatigue[32] ? +    +     
NRS fatigue[38,44]   ?  ?  ?   ?  
VAS fatigue[43]          MID 
SF-36 VT[26,40,50]  ?     –
/++b 
   MID, 
F/C 
PARTICIPATION 
(n=11) 
          
SRPQ-IM[52]  ? + ? +  +    MDC 
SRPQ-ST[52] ? + ? +  +    MDC 
SRPQ-SR[52] ? + ? +  +    MDC 
WPS[57]       +   + F/C 
AIMS1 SA[21]       ?     
AIMS2 SA[24]      ?     
AIMS2 Work[24]      ?     
AIMS2 SC[28]          ?  
SF-36 RE[26,40,50]  ?     ?/++ 
b 
  ?  
SF-36 RP[26,40,50]  ?     –/++ 
b 
  ?  
SF-36 
SF[26,28,40,50]  
?     ?/++ 
b 
  ?  
Table 3 cont 
PROMs by COS 
Domains  
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 COSMIN BOX (A-C) 
Validity 
 COSMIN BOX (D-H) 
Responsive
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COSMIN 
BOX (I) 
Info on 
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tation  
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Internal 
consiste
ncy 
Reliabilit
y 
M
ea
su
re
m
e
nt 
er
ro
r 
Con-
tent 
validi
ty 
Stru
ctu-
ral 
vali
dity 
Hyp
o-
the-
ses 
testi
ng 
Cross
-cult. 
Valid
ity 
Crite
rion 
validi
ty 
Sensitivity 
to change 
(values 
are 
provi-
ded in 
suppl.  
Table 
D) 
 A B C D E F G H I  
EMOTIONAL WELL-BEING (n=9)         
SF-36 
MH[26,28,40,50] 
?     ++ b   ? MID 
SF-36 MCS[40,50]      ++ ?   ?  
MultiP mRAI[44]  ?  ?  ?     
AIMS1 Psyc.C.[25]         ?  
AIMS1 Anxiety[21]      ?     
AIMS1 Depression[21]       ?     
AIMS2 Mood[21]      ?     
AIMS2 Tension[21]      ?     
AIMS2 Psyc.C.[25,28]            ?  
ECONOMIC COST 
(n=4) 
          
EQ-5D 
[42,45,47,48,54,75] 
     ++   ? MCII, 
PASS, 
F/C 
EQ-5D-revised[48]      ?   ? Score 
distribut
ion 
SF-6D[45,47,54]      +   ? PASS, 
MCII, 
F/C 
WTP[46]     ?  +     
SLEEP (n=1)           
VAS sleep[43]          MID 
STIFFNESS (n=2)           
NRS stiffness[44]    ?  ?     
VAS stiffness[22]     ?     
NON-COS Domains (n=2)          
SF-36 GH[26,40,50] ?     – /– 
– b 
    
AIMS2 Social Support[24]     ?     
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Empty cells reflect that the measurement property was not evaluated by any study for the given instrument.  Table 2 
explains the grading of evidence (+/-/?).   
a
Only translation, no cross-cultural validation. According to COSMIN, only studies that address measurement 
invariance (e.g. multiple group factor analyses or DIF) between countries (or other groups) are considered real cross-
cultural validity studies. 
b
Construct validity – hypotheses testing was assessed regarding the internal relationships 
(scale assumptions) and not relation to external measurements. 
c 
Questionnaire seems to be based on a formative 
model why scoring of internal consistency and structural validity is not relevant. 
d 
PsAID touch version was compared 
to paper version which was considered as gold standard. Abbreviations: AIMS, Arthritis Impact Measurement Scales 
(ADL, Activity of daily living; Arm F., Arm Function; House, Household; PC, Physical component score; Psyc.C., 
Psychological component score; SA, Social Activity, SC, Social component score); BASDAI, Bath Ankylosing Spondylitis 
Activity Index; BASFI, Bath Ankylosing Spondylitis Functional index; CIAQ-FI, Combined Inflammatory Arthritis – 
Functional Impairment questionnaire; CIAQ-Qol, Combined Inflammatory Arthritis – quality of life questionnaire; 
COSMIN, COnsensus-based Standards for the selection of health Measurement INstruments; DASH, Disabilities of 
the Arm, Shoulder and Hand Outcome Measure; DFI, Dougados Functional Index; EQ-5D-3L, EuroQoL 5 Dimensions 
questionnaire with 3 response levels; FACIT-Fatigue, Functional Assessment of Chronic Illness Therapy-Fatigue scale; 
F/C, Floor/Ceiling effect;  HAQ, Health Assessment Questionnaire (HAQ-S: Spondyloarthropathy, HAQ-SK: Skin, HAQ-
DI: Disability Index); IPBOD, Inverse Psoriasis Burden of Disease questionnaire; MCID, Minimal clinically important 
difference; MDA, Minimal disease activity; MDC, minimal detectable change; MCII, Minimal clinical important 
improvement; MIC, Minimal important change; MID, Minimal important difference; mRAI, Modified Rheumatology 
Attitude Index; MultiP, Multidimensional Patient Reported Outcome Questionnaire; NRS, Numeric Rating Scale; NS, 
Not stated; PAIP, Psoriatic Arthritis Impact Profile; PASE, PsA Screening and Evaluation Questionnaire; PASS, Patient 
acceptable symptom state; PGA, Patient Global Assessment; PR-TJC, Patient-reported-tender-joint-count; PsAID, 
Psoriatic Arthritis Impact of Disease questionnaire; PsAQoL, PsA Quality of Life instrument; PSD; Psoriasis symptom 
diary; PSI, Psoriasis Symptom Inventory; Psodisk questionnaire, no full spelling available;  SASPA, Stockerau Activity 
Score for Psoriatic Arthritis; SF-6D, utility tool derived from SF-36 comprising six multi-level dimensions; SF-36, 
Medical Outcome Survey Short Form 36-item Health Survey (SF-36 subscales: BP, Bodily Pain; GH, General Health; 
MCS, Mental Component Summary; MH, Mental Health;  PCS, Physical Component Summary, PF, physical function; 
RE, Role Emotional; RP, Role Physical; SF, Social Functioning;  VT, Vitality); SRPQ, Social Role Participation 
Questionnaire; VAS, Visual Analogue Scale;  VITACORA-19, Spanish acronym, full name not available; WTP, 
Willingness to pay questionnaire; WPS, Work Productivity Survey.  
 
DISCUSSION  
Core outcome measurement sets (COMS) aim to ensure the best possible evaluation of the domains in a core 
outcome set (COS) for a specific disease, providing comparability across study results and enhancement of 
evidence-based health care decisions. While previous studies have provided overviews of commonly used 
instruments in PsA,[76,77] this review provides a systematic identification, characterization and evidence 
synthesis of measurement properties of all PROMs evaluated in PsA, which constitutes an important step in 
the GRAPPA-OMERACT process of developing a PsA COMS.   
PROMs with at least some evidence on both reliability and validity are available for six of the eight 
mandatory (“inner circle”) COS domains including MSK disease activity (SASPA), skin disease activity 
(PSI), patient global (VAS global), physical function (SF-36 PF, HAQ-DI, BASFI), HRQoL/life impact 
(PsAID-9, PsAID-12, PsAQoL, VITACORA-19) and fatigue (FACIT-Fatigue).  
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Instruments with strong evidence for any measurement property included HAQ-DI and SF-36 PF (physical 
function domain), PSD (skin disease activity domain), PsAID-9, PsAID-12 and the English version of 
PsAQoL (HRQoL/life impact domain).  The PSD, PsAID-9, PsAID-12, and English PsAQoL had strong 
evidence on content validity, a property that was sparsely investigated for most other PROMs. Content 
validity is considered a prerequisite for applicability of PROMS in PsA clinical trials as emphasized by the 
FDA, OMERACT and the COSMIN-COMET initiative.[17,20,78]  Thus, unknown content validity of 
PROMS is a serious shortcoming that needs attention in PsA – as well as in other rheumatic 
diseases.[58,79,80]  
No PROM with evidence on both reliability and validity was available for the mandatory COS domains of 
systemic inflammation and pain. The absence of a good PROM for assessment of pain is especially critical 
as clinicians and patients have considered this patient-reported domain extremely important according to 
former studies.[5,58] Future research should gain more information on the measurement properties of the 
SF-36 pain subscale, VAS pain and the AIMS pain scale that all had some evidence of validity in PsA 
according to this SLR.  
Furthermore, data from the PsAID study could provide additional evidence for use of the individual NRS for 
several of the COS domains, including pain. The applicability of the Patient Reported Outcomes 
Measurement Information System (PROMIS) for measuring pain as well as other domains of the PsA COS 
may also be considered.[81] PROMIS provides multiple unidimensional instruments that can be 
administered as fixed short forms as well as computer adaptive tests. The SF-36 subscales assess three inner 
core domains (pain, physical function and fatigue/vitality) and a visual representation of the multiple life 
impact/HRQoL domains can be generated through spydergrams.[82] It may seem practical to use a 
questionnaire with multiple scales that cover several domains in one application. However, it is more 
important to endorse the best instrument per domain and further research must be done on the measurement 
properties of SF-36 subscales in PsA.  
All language versions of a PROM were lumped in the main evidence synthesis of this review to achieve as 
much information as possible per instrument. This strategy underscores the importance of collecting 
sufficient evidence on cross-cultural validity prior to international application of a PROM. For instance, the 
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German SASPA (MSK disease activity) and the Italian/Turkish VITACORA-19 (HRQoL) both have some 
evidence for reliability and validity but translation (and cross-cultural validation) into the most common 
languages (English at least) is warranted. Furthermore, the evidence for content validity of PsAQoL and 
construct validity of HAQ-DI was rated as conflicting in the overall synthesis mainly due to diverging 
results across language versions. Given the limited number and quality of the included studies, future studies 
of high methodological standards should clarify if such differences truly exist and if they are cross-culturally 
related. Several studies evaluated the measurement properties of a translated questionnaire but according to 
COSMIN, only studies that address measurement invariance (e.g. multiple group factor analyses or DIF) 
between countries (or other groups) are considered real cross-cultural validity studies.     
Few studies with sufficient methodology for assessing responsiveness were identified. Although reliability 
and validity were considered preconditions for potential PROMs, the COMS is being developed for clinical 
trials for which measuring the true amount of change in a construct during an intervention is often the 
primary goal. Therefore, responsiveness of promising instruments needs to be clarified in future studies.      
The evidence for measurement properties of PROMs measuring skin disease activity was limited since we 
included only studies with at least 50% of the population comprising PsA patients (or PsA subgroup results). 
This strategy may be conservative, for instance additional information on the candidate instrument PSI as 
well as on PSD would have been achieved by including studies of psoriasis.[83-86] Nevertheless, our 
strategy ensures that the evidence obtained applies to patients with PsA as a whole.  
Strengths of this GRAPPA-OMERACT study constitute the international collaboration including experts in 
PsA, measurement and systematic review technique as well as patient research partners. Adherence to the 
COSMIN guidelines guaranties homogeneity and transparency in the assessment of methodology and rating 
of measurement properties across studies. Study limitations include, as for reviews in general, that negative 
findings might have been underreported due to publication bias. Selection bias due to exclusion of non-
English full-text papers may have led to underreporting of the (cross-cultural) evidence for some 
instruments. However we believe this was minimized as only five studies were excluded for this reason. 
This review did not include RCTs or longitudinal observational studies that only provide indirect evidence 
for measurement properties of instruments used for assessing the outcomes of interest. We acknowledge that 
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great amounts of indirect evidence are available and valuable in the COMS development. However the 
identification, selection and evaluation strategies needed for such studies do not comply with the 
methodology of the current review. Further analyses are currently underway by parallel work streams 
evaluating the data from PROMs collected in recently conducted RCTs of interventional therapies in PsA to 
fully adhere to the OMERACT procedure of COMS development.  
This study provides an evidence based overview of measurement properties of PROMs per COS domain. 
We have highlighted the current knowledge gaps, and provided an overview of available data on score 
interpretation, feasibility and content for each PROM. This constitutes a relevant starting point for 
stakeholders to decide on the overall applicability of the PROMs, and provides opportunities to improve 
existing data by targeted research strategies.[6,10] This is indeed warranted as several of the PROMs with 
elusive measurement properties are widely used in PsA trials and clinics today. [77] Some COS domains 
may be more appropriately assessed by non-PROM instruments such as biomarkers and clinical 
assessments, and parallel work streams within GRAPPA-OMERACT are collecting psychometric evidence 
for the use of such tools in PsA.  These research initiatives will in addition to the psychometric evidence for 
PsA PROMs presented in this review inform the consecutive stages of developing a COMS for PsA.  
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